The range of therapeutic efficacy of atypical antipsychotics: A critical evaluation

Medical Hypotheses

Volumn 61, Issue 2, 2003, Pages 259-264

  Dimova, Aleksandra ^a  

^a SINN Social Innovative Network   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; TOPIRAMATE; TRANQUILIZER; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGGRESSION; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EPILEPTIC STATE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MANIA; MOOD DISORDER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0042122390     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00157-9     Document Type: Article

References (34)

1. Buckley P. F. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001; 50(11): 912-924.
2. Ohaeri J. U. Naturalistic study of olanzepine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder. East Afr Med J 2000; 77(2): 86-92.
3. Leucht S., Pitschel-Walz G., Engel R. R. et al. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159(2): 180-190.
4. Bhana N., Foster R. H., Olney R. et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61(1): 111-161.
5. Dev V., Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf 2000; 23(4): 295-307.
6. Stahl S. M. Psychopharmacology of antipsychotics. Martin Dunitz 1999.
7. Xiberas X., Martinot J. L., Mallet L. et al. Extrastriatal and striatal D (2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179: 503-508.
8. Brieden T., Ujeyl M., Naber D. Psychopharmacological treatment of aggression in schizophrenic patients. Pharmacopsychiatry 2002; 35(3): 83-89.
9. Baker A. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. Poster presented at schizophrenia Winterworkshop, Davos 2002.
10. Cookson J. Use of antipsychotic drugs and lithium in mania. Br J Psychiatry Suppl 2001; 41: s148-s156.
11. Sanger T. M., Grundy P. J., Gibson P. J. et al. Long-term olanzapie therapy in the treatment of bipolar I disorder. An open-label continuation phase study. J Clin Psychiatry 2001; 62(4): 273-281.
12. Rothschild A. J., Bates K. S., Boehringer K. L. et al. Olanzepine response in psychotic depression. J Clin Psychiatry 1999; 60(2): 116-118.
13. Weizman R., Weizman A. Use of atypical antipsychotics in mood disorders. Curr Opin Invest Drugs 2001; 2(7): 940-945.
14. Konig F., von Hippel C., Petersdorff T. et al. First experiances in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobilogy 2001; 43(3): 170-174.
15. Adli M., Rossius W., Bauer M. Olanzapine in the treatment of depressive disorders with psyhotic symptoms. Nervenarzt 1999; 70(1): 68-71.
16. Schmitt A., Braus D. F. Effective treatment of depressive disorder with psychoptic symptoms by olanzapine combination therapy. Dtsch Med Wocheschr 2000; 125(50): 1526-1529.
17. Weintraub E., Robinson C. A case of monosymptomatic hypohondriacal psychosis treated with olanzapine. Ann Clin Psychiatry 2000; 12(4): 247-249.
18. Shelton R. C., Tollefson G. D., Thoen M. et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158(1): 131-134.
19. Weisler R. H., Ahearn E. P., Davidson J. R. et al. Adjuctive use of olanzepine in mood disorders: five case reports. Ann Clin Psychiatry 1997; 9(4): 259-262.
20. Thase M. E. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 2002; 63(2): 95-103.
21. Ghaemi S. N. New treatments for bipolar disorders: the role of atypical neuroleptics agents. J Clin Psychiatry 2000; 61(Suppl. 14): 33-42.
22. Parker G, Malhi G. Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry 2001; 35(5): 631-638.
23. Nelson L. A., Swartz C. M. Melancholic symptoms during concurrent olanzapine and fluoxetine. Ann Clin Psychiatry 2000; 12(3): 167-170.
24. Tollefson G. D., Andersen S. W., Tran P. V. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomised comparition of olanzapine and risperidone. Biol Psychiatry 1999; 46(3): 365-373.
25. Peuskens J., Moller H. J., Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. J Eur Neuropsychopharmacol 2002; 12(4): 305-310.
26. Mitchell P. B. The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder. Aust N Z J Psychiatry 1999; 33(Suppl): S99-S107.
27. Pillman F., Schlote K., Broich K. et al. Encephalogram alternations during treatment with olanzapine. Psychopharmacology (Berl) 2000; 150(2): 216-219.
28. Wyderski R. J., Starrett W. G., Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother 1999; 33(7-8): 787-789.
29. Centorrino F., Price B. H., Tuttle M. et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002; 159(1): 109-115.
30. Pisani F., Oteri G., Costa C. et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25(2): 91-110.
31. Yokota K., Tatebayashi H., Matsuo T. et al. The effects of neuroleptics on the GABA-induced Cl-current in rat dorsal root ganglion neurons: differences between some neuroleptics. Br J Pharmacol 2002; 135(6): 1547-1555.
32. Kapur S., Seeman P. Does fast dissociation from D (2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158(3): 360-369.
33. Kapur S., Zipursky R., Jones C. et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57(6): 553-559.
34. Silvestri S., Seeman M. V., Negrete J. C. et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000; 152(2): 174-180.